Abstract Body

Background

Long-term delivery of potent and broadly neutralizing antibodies (bNAbs) via adeno-associated virus (AAV) vectors offers a promising strategy for HIV prevention.

Methods

Four Indian-origin rhesus macaques received a one-time intramuscular administration of AAV9 encoding bNAb PCIN63, a CD4 binding site antibody with the hallmark VRC01-class features and similar neutralization breadth but with significantly less somatic hypermutation. Four weeks later, low-dose intrarectal challenges with Simian-Human Immunodeficiency Virus (SHIV)-AD8 occurring every 2 weeks were performed. Infection was monitored by plasma viral load, and PCIN63 levels were measured in both serum and mucosal samples by Enzyme-Linked Immunosorbent Assay (ELISA).

Results

All four macaques successfully expressed PCIN63, with peak levels in serum ranging from 53-119 µg/mL. Two of four (50%) of the macaques showed sustained high serum levels of PCIN63 (~20 µg/mL) for over 24 weeks after AAV administration. These two macaques showed detectable PCIN63 in mucosal samples. After ten challenges, 75% (3/4) of the AAV recipient macaques remained uninfected while 75% (3/4) of the untreated controls were infected. Additional challenges and measurements are underway.

Conclusions

Sustained PCIN63 expression at relatively high levels can be achieved with a single dose of AAV. AAV-expressed PCIN63 can reach mucosal surfaces, demonstrating effective biodistribution to relevant sites of viral entry. AAV-PCIN63 recipients exhibited a 67% reduced risk of infection compared to controls, indicating clearly measurable protection. Our findings demonstrate the potential and feasibility of using AAV vectors to deliver bNAbs capable of mucosal localization and protection against viral acquisition.